Zur Kurzanzeige

dc.contributor.authorKoehl, Niklas
dc.contributor.authorKuentz, Martin
dc.date.accessioned2021-05-10T07:37:55Z
dc.date.available2021-05-10T07:37:55Z
dc.date.issued2020-06-10
dc.identifier.doi10.1007/s11095-020-02841-9
dc.identifier.urihttps://irf.fhnw.ch/handle/11654/32421
dc.description.abstractConclusion: Chase dosed LBF enhanced the in vivo bioavailability of nilotinib. Long chain lipids showed superior performance compared to medium chain lipids. Chase dosing appeared to prolong the absorption phase of the drug. Therefore, chase dosing of LBF is favourable compared to lipid suspensions for 'brick dust' molecules such as nilotinib. Graphical Abstract The potential of bio-enabling lipid vehicles, administered via chase dosing and lipid suspensions, has been evaluated as an approach to enhance oral bioavailability of nilotinib.en_US
dc.description.urihttps://pubmed.ncbi.nlm.nih.gov/32524365/en_US
dc.language.isoenen_US
dc.relation.ispartofPharmaceutical Researchen_US
dc.accessRightsAnonymous*
dc.subjectbrick dust moleculeen_US
dc.subjectchase dosingen_US
dc.subjectlipid based formulationen_US
dc.subjectpoorly water-soluble drugsen_US
dc.titleChase Dosing of Lipid Formulations to Enhance Oral Bioavailability of Nilotinib in Ratsen_US
dc.type01 - Zeitschriftenartikel, Journalartikel oder Magazin*
dc.volume37en_US
dc.issue7en_US
dc.audienceScienceen_US
fhnw.publicationStatePublisheden_US
fhnw.ReviewTypeAnonymous ex ante peer review of a complete publicationen_US
fhnw.InventedHereYesen_US
fhnw.PublishedSwitzerlandYesen_US
fhnw.pagination124en_US
fhnw.IsStudentsWorknoen_US
fhnw.publicationOnlineJaen_US


Dateien zu dieser Ressource

DateienGrösseFormatAnzeige

Zu diesem Eintrag gibt es keine Dateien.

Der Eintrag erscheint in:

Zur Kurzanzeige